美国Bayer公司生物技术分公司在研制可溶性蛋白预防鼻病毒感染方面已取得重大进展.公司认为他们的感冒预防剂可望在两年后进行人体试验.研究人员研制出一种可溶性细胞间粘附分子1(ICAM-1),鼻病毒在感染鼻腔细胞前是通过它固定于鼻腔的.他们制备出一种截短的ICAM-1基因,后者缺失ICAM-1跨膜区的编码基因,而该区域恰好是粘附于鼻腔细胞受体的部分.将这种截短的基因插入仓鼠 Significant progress has been made in the development of soluble proteins for the prevention of rhinovirus infections by Bayer Biotech, a division of the United States, which the company believes will be capable of human trials two years from now .. The researchers developed a soluble intercellular adhesion molecule 1 (ICAM-1), through which the rhinovirus is fixed in the nasal cavity prior to infection of nasal cells, they prepared a truncated ICAM-1 gene that lacks the coding gene for the transmembrane region of ICAM-1, The region happens to be the part of the nasal cell receptor that is attached to. This truncated gene is inserted into the hamster